Total FST was significantly upregulated in primary myeloblasts obtained from FLT3/ITD AML patients relative to those in mobilized peripheral blood stem cells (PBSCs) from healthy donors (Fig 2P) and FLT3/WT AML samples (Appendix Fig S2E–G). This evidence concerns the gene FLT3 and acute myeloid leukemia.